Analyst Speak:

 

“The Global Companion Diagnostics Market is expected to reach US$ 6,988.7 Mn by 2025 owing to growth in R&D for the development of new technologies”

 

The global companion diagnostics market is expected to reach US$ 6,988.7 Mn by 2025. A companion diagnostic is a diagnostic test which is used as a companion to a therapeutic drug to determine its applicability to a specific person. Companion diagnostics are majorly used in oncology area. The factors which are driving the growth of global companion diagnostics market are improvement in healthcare sector, emergence of new pharmaceuticals and diagnostics, and accelerated drug regulatory approvals. Additionally, increased partnership of market players with research institutes, and rising of governmental funds in the research projects are also streaming the growth of global companion diagnostics market in coming years. However, complex clinical trial procedures, higher cost of research and development, and stringent regulatory approvals for the products are hindering the growth of global companion diagnostics market.

 

Global Companion Diagnostics Market is segmented on the application, technology, end user and region.

 

Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=15987

Gene Sequencing Dominate the Global Companion Diagnostics Market

 

Based on the technology, global companion diagnostics market is segmented into evaporative real-time PCR, gene sequencing, immunohistochemistry, molecular diagnostics, in-situ hybridization, FISH, and CISH. Gene sequencing dominated the global companion diagnostics market due to its better sensitivity and specificity, faster identification of genetic diseases, and technological advancements in the gene sequencing technique.

 

North America Leads the Global Companion Diagnostics Market

 

PBI’s global companion diagnostics market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America dominated the global Companion Diagnostics market through 2014-2018 and expected to dominate over 2019-2025 owing to its improved healthcare facilities, technological advancements, and presence of key market players in the region. In North America, U.S and Canada are leading the market due to the presence of a large number of leading companion diagnostics vendors & national clinical laboratories. Asia Pacific companion diagnostics market is estimated to grow significantly in the forecast period due to their rising population, increasing demand for advanced therapies, emerging economies, and increasing awareness among the population about these companion diagnostics technologies.

Launch of newer technologies, and strategic alliances are the key strategies adopted by market players

 

Global companion diagnostics market further reveals that the key player’s increasingly adopting strategies such as launch of technologies, and long term alliance to improve market revenue share and gaining significant geographic presence across the region.

For instance, in April 2019, QIAGEN and LabCorp collaborated to provide day-one access for patients to innovative companion diagnostics at the time of drug approvals. They will be able to provide physicians and patients with faster access to new, gnomically targeted drugs that are becoming increasingly important therapies for a growing variety of cancers.

 

Key player’s profiles in the report are F. Hoffmann- La Roche Ltd. (Switzerland), Danaher (U.S), Qiagen Ltd. (Germany), Myriad Genetics Inc. (U.S), ARUP Laboratories (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific (U.S), Ventana Medical Systems Inc. (U.S), LabCorp (US), and Biogenex Laboratories, Inc. (U.S).

 

For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostics-market/

Precision Business Insights (PBI) in its report titled “Global Companion Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

 

Detailed Segmentation

 

By Application

• Urology
• Melanoma
• Gastric Cancer
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Others

 

By Technology

• Real-Time PCR
• Gene Sequencing
• Immunohistochemistry
• Molecular Diagnostics
• In-situ Hybridization
• FISH
• CISH

 

By End User

• Hospitals
• Diagnostic Centers
• Others

 

Geography

 

• North America

• US
• Canada

• Europe

• Germany
• France
• UK
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

• Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

• Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

• Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

 

About Us:
 
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
 
Contact Us:
 
Shreya Paul
Senior Business Development Executive
Email @ shreya@precisionbusinessinsights.com
Call @ +1-866-598-1553
Precision Business Insights